Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Breast 1

Conditions

Cholangiocarcinoma 6Gastrointestinal Neoplasms 3Carcinoma, Transitional Cell 3Breast Neoplasms 3Pancreatic Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Solid Tumor, Miscellaneous 1Solid Tumor 1Sarcoma 1Recurrence 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lung Neoplasms 1Locally Advanced Unresectable Gastric Cancer 1Liposarcoma 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Gastrointestinal Stromal Tumors 1Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel 1Digestive System Neoplasms 1Advanced Non-Small Cell Lung Cancer 1Advanced Non Small Cell Lung Cancer 1

Interventions

Oxaliplatin 18Surveys and Questionnaires 15Fluorouracil 15Capecitabine 13Leucovorin 12Blood Specimen Collection 11Irinotecan 10Standard of Care 7Cisplatin 7Endoscopic Mucosal Resection 6atezolizumab 5Specimen Handling 5Radiotherapy 5Educational Status 5Drug Therapy 5Docetaxel 5S 1 (combination) 4Radiosurgery 4Nivolumab 4Magnetic Resonance Spectroscopy 4Interviews as Topic 4Gemcitabine 4Everolimus 4Colonoscopy 4Biopsy 4Bevacizumab 4tegafur-gimeracil-oteracil 3pemigatinib 3apatinib 3Remote Patient Monitoring 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Gastrointestinal Neoplasms × pemigatinib × Clear all
NCT04591431 2023-10-03

ROME

Fondazione per la Medicina Personalizzata

Phase 2 Unknown
400 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT05651672 2022-12-15

Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Recruiting
100 enrolled
Gastrointestinal

Gastrointestinal Neoplasms

NCT05559775 2022-09-29

A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastrointestinal Cancer (Excluding Biliary Tract Cancer) Patients With FGFR Alterations Who Have Failed Standard Therapy

Zhejiang Cancer Hospital

Phase 2 Unknown
20 enrolled
Gastrointestinal

Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡